Full Press Release Details
• Company Update
• By Turn Therapeutics
• October 8, 2025
[Update October 9, 2025: This event has ended]
Tune in live at 3:45PM ET to join the celebration
Share
TTRX Positive Sentiment
Turn Therapeutics ($TTRX) to Ring the Closing Bell at Nasdaq
Key Takeaway: Turn Therapeutics recently celebrated a milestone by ringing the closing bell at Nasdaq. The event highlighted the company's achievements and its innovative GX-03 technology, which has been recognized for its impact on atopic dermatitis treatment. CEO Bradley Burnam's engagement with healthcare leaders further underscores the company's growing influence in the biopharma sector.
Price reaction · baseline $10 (2025-10-08 open) · hit during market hours · 2 other TTRX headline(s) in the window, move may be shared
day 0 close
-30%
day 1
-8%
day 3 · peak
-34.9%
Market Sentiment Analysis
POSITIVE FACTORS
- Turn Therapeutics is gaining recognition in the industry.
- The company is celebrating a significant milestone at Nasdaq.
- CEO Bradley Burnam is engaging with notable figures in healthcare.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~32 mo
Minimal dilution risk
Lead asset
GX-03
Phase 2 · Covid19
Frequently Asked Questions
What event did Turn Therapeutics recently celebrate?
Turn Therapeutics celebrated by ringing the closing bell at Nasdaq.
Who is the CEO of Turn Therapeutics?
The CEO of Turn Therapeutics is Bradley Burnam.
What technology is recognized by Patient Care Online?
Turn Therapeutics' GX-03 technology is recognized for reshaping atopic dermatitis treatment.
Who did Bradley Burnam speak with recently?
Bradley Burnam spoke with former CDC Director Dr. Robert Redfield.